| Literature DB >> 30008787 |
Storm N S Reid1, Je-Kwang Ryu2, Yunsook Kim3, Byeong Hwan Jeon1.
Abstract
Considering the neuroprotective and antioxidant potential of fermented Laminaria japonica A. (FST), the purpose of the present study is to establish whether FST may be considered a viable, efficacious supplement that can be administered in later life to offset neurodegenerative conditions associated with aging. Forty senior subjects participated in a randomized, double-blind, and placebo-controlled study. Two groups were formed, one FST group (n = 32, 72.35 ± 5.54 yrs) and one placebo (CON) (n = 28, 74.57 ± 5.69 yrs), which received 1.5 g/day of FST for 6 weeks. Subjects were asked to abstain from any regular exercise. In order to analyze short-term memory, a variety of neuropsychological tests were implemented. Body composition, physical fitness evaluations, antioxidant function, and inflammatory markers were also included in the analyses pre- and posttest. We demonstrated that FST significantly improved neuropsychological test scores, including higher scores in the K-MMSE, numerical memory test, Raven test, and iconic memory, compared to the CON group. Shorter test trial times in the 6-meter [corrected] walk test were observed in the FST group (p<0.001 and p<0.05, trials 1 and 2, respectively). FST also significantly increased antioxidant activity of GPx, GSR, and SOD, reduced the production of TBARS, and lowered 8-oxoDG levels. The present study highlights the potential widespread application of FST in protecting against the degenerative effects of aging on short-term memory and physical function. Neuropsychological evaluation indicates that FST may provide a protective mechanism against cognitive impairment associated with dementia. Neuromuscular integrity and physical function are typically compromised in aging and dementia patients; thus, whether by stimulation of muscle-related growth factors or an increase in serum BDNF, FST supplementation may act to preserve physical function in the elderly. The bioactive constituents of FST such as GABA and fucoidan acting to provide improvements in antioxidant activity following FST supplementation may protect against progressive degeneration purportedly caused by reactive oxygen species.Entities:
Year: 2018 PMID: 30008787 PMCID: PMC6020467 DOI: 10.1155/2018/8109621
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Participant characteristics.
| Placebo (n=32) | Treatment (n=28) | |
|---|---|---|
| Age (years) | 74.57 ± 5.69 | 72.35 ± 5.54 |
| Height (cm) | 153.47 ± 6.68 | 157.70 ± 5.84 |
| Weight (kg) | 54.20 ± 7.35 | 59.30 ± 6.93 |
Culture broth composition.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| Weight (g) | 408.5 | 6,127.5 | 10 | 5 | 76.5 | 6,627.5 |
| Percentage (%) | 6.2 | 92.5 | 0.2 | 0.1 | 1.2 | 100 |
γ-aminobutyric acid-enriched fermented sea tangle : water = 1 : 15 (w/v). Reprinted from “effects of γ-aminobutyric acid-enriched fermented sea tangle (Laminaria japonica) on brain derived neurotrophic factor-related muscle growth and lipolysis in middle aged women,” Algae, vol. 31, no. 2, pp. 177, 2016. Reprinted with permission.
Figure 1Preparation process of y-aminobutyric acid- (GABA-) enriched fermented sea tangle (FST) from raw sea tangle. Adapted from “effects of γ-aminobutyric acid-enriched fermented sea tangle (Laminaria japonica) on brain-derived neurotrophic factor-related muscle growth and lipolysis in middle-aged women,” Algae, vol. 31, no. 2, pp. 177, 2016. Adapted with permission.
Pre and posttest comparison results of neuropsychological and physical fitness assessment using t-test analysis, between FST group and placebo group.
| FST | Placebo |
|
| ||||
|---|---|---|---|---|---|---|---|
|
| Difference |
| Difference | ||||
| K-MMSE | pre | 26.31(1.78) | 1.59(1.49) | 26.35(2.79) | .39(1.85) | 2.773 | .007 |
| post | 27.90(1.57) | 26.75(3.52) | |||||
|
| |||||||
| Numerical memory test | pre | 7.78(.42) | .62(.90) | 7.92(.85) | .10(.99) | 2.110 | .039 |
| post | 8.40(.87) | 8.03(1.23) | |||||
|
| |||||||
| Raven's test | pre | 11.06(5.29) | 2.37(3.63) | 12.25(5.10) | −1.67(2.85) | 4.754 | .000 |
| post | 13.43(6.17) | 10.57(4.51) | |||||
|
| |||||||
| Flanker test | pre | 1785.95(385.77) | −549.18 | 1785.36(457.92) | −610.36 | .247 | .806 |
| post | 1068.92(279.10) | 1036.27(344.85) | |||||
|
| |||||||
| Iconic memory test (pre) | pre | .45(.20) | .15(.23) | .48(.22) | .05(.22) | 1.606 | .114 |
| post | .61(.13) | .54(.17) | |||||
|
| |||||||
| Iconic memory test (simultaneous) | pre | .22(.13) | .16(.12) | .25(.11) | .05(.10) | 3.673 | .001 |
| post | .39(.10) | .31(.14) | |||||
|
| |||||||
| Iconic memory test (post) | pre | .15(.09) | .10(.11) | .18(.09) | .018(.12) | 2.660 | .010 |
| post | .26(.11) | .20(.10) | |||||
|
| |||||||
| TMT | pre | 66.99(29.94) | −5.39(15.48) | 77.38(34.37) | −10.98(26.13) | 1.024 | .310 |
| post | 61.60(20.43) | 65.98(32.96) | |||||
|
| |||||||
| 6MW (1) | pre | 4.81(.61) | −.32(.46) | 4.64(.75) | .26(.40) | −5.232 | .000 |
| post | 4.48(.43) | 4.90(.66) | |||||
|
| |||||||
| 6MW (2) | pre | 4.65(.93) | −.11(.55) | 4.53(.83) | .38(.57) | −3.382 | .001 |
| post | 4.54(.66) | 4.91(.81) | |||||
|
| |||||||
| TUG (1) | pre | 6.96(.96) | −.14(1.35) | 6.59(.90) | 1.25(.75) | −4.861 | .000 |
| post | 6.82(.73) | 7.84(1.27) | |||||
|
| |||||||
| TUG (2) | pre | 7.01(.99) | −.29(1.17) | 6.60(.97) | 1.45(1.31) | 1.063 | .292 |
| post | 6.71(.70) | 8.05(1.75) | |||||
Figure 2Serum (a) GPx, (b) GSR, (c) SOD, (d) TBARS, and (e) 8-oxoDG levels were determined in the FST and placebo group, pre- and postexperimental trial. Each bar represents the mean ± SD. Student's paired t-tests were carried out to determine significant differences (∗p < 0.05, ∗∗p < 0.001) between the FST and placebo groups.
Figure 3Changes in serum growth-related markers: (a) HGH, (b) IGF-1, and (c) BDNF levels were determined in the FST and placebo group, pre- and postexperimental trial. Each bar represents the mean ± SD. Student's paired t-tests were carried out to determine significant differences (∗p < 0.05, ∗∗p < 0.001) between the FST and placebo groups.